CN108938599A - A kind of double medicament-carried nano carriers of cancer target - Google Patents
A kind of double medicament-carried nano carriers of cancer target Download PDFInfo
- Publication number
- CN108938599A CN108938599A CN201811113542.4A CN201811113542A CN108938599A CN 108938599 A CN108938599 A CN 108938599A CN 201811113542 A CN201811113542 A CN 201811113542A CN 108938599 A CN108938599 A CN 108938599A
- Authority
- CN
- China
- Prior art keywords
- cancer target
- polypeptide
- carried nano
- nano carriers
- double
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5115—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Physics & Mathematics (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a kind of double medicament-carried nano carriers of cancer target, including big-pore mesoporous silica, the big-pore mesoporous silica surface covers poly lactide-glycolide acid, and poly lactide-glycolide acid deposits poly-dopamine coating after polyethyleneglycol modified and is fixed with polypeptide.The aperture of the big-pore mesoporous silica is 11~14nm or so.Cancer target of the present invention pair medicament-carried nano carriers can pass release system as the double medicines that carry of cancer target, and have good water solubility, good biocompatibility, degradable, entrapment efficiency height, the advantages such as degradation rate is fast, and tumor-targeting is strong, and cytotoxicity is low.
Description
Technical field
The present invention relates to biomedical engineering fields, and in particular to a kind of double medicament-carried nano carriers of cancer target.
Background technique
According to statistics, malignant tumour is to be only second to the second largest killer of cardiovascular and cerebrovascular disease, and current most of patient is
It is treated by operation excision, radiotherapy and chemicals.These therapies can get infantile tumour patient fast and effective
Therapeutic effect fail to the life cycle and the improvement that significantly extend patient but to advanced stage with the patient of local diffusion and transfer
The life quality of patient, and toxic side effect is larger.In recent years, the study found that cancer is a kind of genopathy, be human body cell outside
Under the action of environmental factor, inherent a variety of preceding oncogenes are activated the process with the multistage long term evolution of tumor suppressor gene inactivation.
Therefore, by chemotherapy in conjunction with gene therapy, to raising oncotherapy effect important in inhibiting.
Gene therapy needs to import foreign gene in target cell by suitable carrier, enables genomic medicine across body
The various barriers of interior environment, are transported to target cell, realize the high efficient expression of drug.Currently, existing nanometer medicine-carried system
That there are still tumour-specifics is lower, cytotoxicity is larger, it is biodegradable it is slow, be unable to control the problems such as drug release, limit it
Using.
Summary of the invention
To solve the above problems, will can change simultaneously the present invention provides a kind of double medicament-carried nano carriers of cancer target
It treats drug and genomic medicine targeting is transported in tumor tissues, and with tumor-targeting is strong, cytotoxicity is low, degradation rate is fast
The advantages that.
To achieve the above object, the technical scheme adopted by the invention is as follows:
A kind of double medicament-carried nano carriers of cancer target, including big-pore mesoporous silica, the big-pore mesoporous dioxy
SiClx surface covers poly lactide-glycolide acid, and poly lactide-glycolide acid deposits poly- after polyethyleneglycol modified
Dopamine coating is simultaneously fixed with polypeptide.
Further, the aperture of the big-pore mesoporous silica is 11~14nm or so.
Further, the polypeptide is TfR specific polypeptide.
Further, the TfR specific polypeptide includes T7 polypeptide.
Further, the mass ratio of the polyethylene glycol and polypeptide is 1~5:1.
Further, the mass ratio of poly lactide-glycolide acid and polypeptide is 4~10:1.
Using big-pore mesoporous silica as kernel in the present invention, can be not only used for supporting hydrophobic small molecule anti-cancer
Medicine, and show the good ability for supporting macromolecular, poly lactide-glycolide acid shell can pass through carrying gene medicine
Object plays drug synergy to form double load drug carriers.Poly lactide-glycolide acid case surface is through PEG and more
Peptide modification, and deposits poly-dopamine coating, can its significant cell compatibility, while surface polypeptide modification can then improve tumor target
Tropism, and tumour cell is improved to the intake of this nano-carrier, improve neoplasm targeted therapy effect.Tumour of the present invention
Double medicament-carried nano carriers are targeted, release system can be passed as the double medicines that carry of cancer target, and there is good water solubility, biocompatibility
Good, degradable, entrapment efficiency is high, the advantages such as degradation rate is fast, and tumor-targeting is strong, and cytotoxicity is low.
Specific embodiment
The present invention is described in detail combined with specific embodiments below.Following embodiment will be helpful to the technology of this field
Personnel further understand the present invention, but the invention is not limited in any way.It should be pointed out that the ordinary skill of this field
For personnel, without departing from the inventive concept of the premise, various modifications and improvements can be made.These belong to the present invention
Protection scope.
Embodiment 1
A kind of double medicament-carried nano carriers of cancer target, including big-pore mesoporous silica, the big-pore mesoporous dioxy
SiClx surface covers poly lactide-glycolide acid, and poly lactide-glycolide acid deposits poly- after polyethyleneglycol modified
Dopamine coating is simultaneously fixed with polypeptide.The aperture of the big-pore mesoporous silica is 11nm or so.The polypeptide is to turn
Human Placental Ferritin Receptor specific polypeptide, the TfR specific polypeptide include T7 polypeptide, the polyethylene glycol and more
The mass ratio of peptide is 1:1, and the mass ratio of poly lactide-glycolide acid and polypeptide is 4:1.
Embodiment 2
A kind of double medicament-carried nano carriers of cancer target, including big-pore mesoporous silica, the big-pore mesoporous dioxy
SiClx surface covers poly lactide-glycolide acid, and poly lactide-glycolide acid deposits poly- after polyethyleneglycol modified
Dopamine coating is simultaneously fixed with polypeptide, and the aperture of the big-pore mesoporous silica is 14nm or so.The polypeptide is to turn
Human Placental Ferritin Receptor specific polypeptide.The TfR specific polypeptide includes T7 polypeptide.The polyethylene glycol and more
The mass ratio of peptide is 5:1, and the mass ratio of poly lactide-glycolide acid and polypeptide is 10:1.
Embodiment 3
A kind of double medicament-carried nano carriers of cancer target, including big-pore mesoporous silica, the big-pore mesoporous dioxy
SiClx surface covers poly lactide-glycolide acid, and poly lactide-glycolide acid deposits poly- after polyethyleneglycol modified
Dopamine coating is simultaneously fixed with polypeptide.The aperture of the big-pore mesoporous silica is 12nm or so.The polypeptide is to turn
Human Placental Ferritin Receptor specific polypeptide.The TfR specific polypeptide includes T7 polypeptide.The polyethylene glycol and more
The mass ratio of peptide is 3:1.The mass ratio of poly lactide-glycolide acid and polypeptide is 7:1.
Specific embodiments of the present invention are described above.It is to be appreciated that the invention is not limited to above-mentioned
Particular implementation, those skilled in the art can make a variety of changes or modify within the scope of the claims, this not shadow
Ring substantive content of the invention.In the absence of conflict, the feature in embodiments herein and embodiment can any phase
Mutually combination.
Claims (6)
1. a kind of double medicament-carried nano carriers of cancer target, it is characterised in that: including big-pore mesoporous silica, the large aperture
Meso-porous titanium dioxide silicon face covers poly lactide-glycolide acid, and poly lactide-glycolide acid is through polyethyleneglycol modified
Poly-dopamine coating is deposited afterwards and is fixed with polypeptide.
2. the double medicament-carried nano carriers of a kind of cancer target as described in claim 1, it is characterised in that: described big-pore mesoporous two
The aperture of silica is 11~14nm.
3. the double medicament-carried nano carriers of a kind of cancer target as described in claim 1, it is characterised in that: the polypeptide is to turn iron
Protein receptor specific polypeptide.
4. the double medicament-carried nano carriers of a kind of cancer target as claimed in claim 3, it is characterised in that: the transferrins by
Body specific polypeptide includes T7 polypeptide.
5. the double medicament-carried nano carriers of a kind of cancer target as described in claim 1, it is characterised in that: the polyethylene glycol and more
The mass ratio of peptide is 1~5:1.
6. the double medicament-carried nano carriers of a kind of cancer target as described in claim 1, it is characterised in that: poly lactic-co-glycolic acid
The mass ratio of copolymer and polypeptide is 4~10:1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811113542.4A CN108938599A (en) | 2018-09-25 | 2018-09-25 | A kind of double medicament-carried nano carriers of cancer target |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811113542.4A CN108938599A (en) | 2018-09-25 | 2018-09-25 | A kind of double medicament-carried nano carriers of cancer target |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108938599A true CN108938599A (en) | 2018-12-07 |
Family
ID=64471803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811113542.4A Pending CN108938599A (en) | 2018-09-25 | 2018-09-25 | A kind of double medicament-carried nano carriers of cancer target |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108938599A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110170057A (en) * | 2019-04-08 | 2019-08-27 | 嘉兴市第二医院 | A kind of nanometer grain preparation method of the double medicines of the load of Tf modification and its application |
| CN110314151A (en) * | 2019-08-02 | 2019-10-11 | 深圳国佳产业基金管理有限公司 | Medical Metaporous silicon dioxide material and its application |
| CN110652518A (en) * | 2019-05-05 | 2020-01-07 | 海南亚洲制药股份有限公司 | Targeting type nano drug-loading system and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160166512A1 (en) * | 2014-12-12 | 2016-06-16 | New Jersey Institute Of Technology | Porous Hollow Fiber Anti-Solvent Crystallization-Based Continuous Method of Polymer Coating on Submicron and Nanoparticles |
| CN106806344A (en) * | 2017-02-17 | 2017-06-09 | 清华大学深圳研究生院 | Poly-dopamine and the mesoporous silicon dioxide nano particle of TPGS modification and preparation method and application |
| CN107260706A (en) * | 2017-06-21 | 2017-10-20 | 广州博徕斯生物科技有限公司 | Double medicament-carried nano carriers of a kind of cancer target and preparation method thereof |
-
2018
- 2018-09-25 CN CN201811113542.4A patent/CN108938599A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160166512A1 (en) * | 2014-12-12 | 2016-06-16 | New Jersey Institute Of Technology | Porous Hollow Fiber Anti-Solvent Crystallization-Based Continuous Method of Polymer Coating on Submicron and Nanoparticles |
| CN106806344A (en) * | 2017-02-17 | 2017-06-09 | 清华大学深圳研究生院 | Poly-dopamine and the mesoporous silicon dioxide nano particle of TPGS modification and preparation method and application |
| CN107260706A (en) * | 2017-06-21 | 2017-10-20 | 广州博徕斯生物科技有限公司 | Double medicament-carried nano carriers of a kind of cancer target and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| YANNA CUI等: "Transferrin-conjugated magnetic silica PLGA nanoparticles loaded with doxorubicin and paclitaxel for brain glioma treatment", 《BIOMATERIALS》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110170057A (en) * | 2019-04-08 | 2019-08-27 | 嘉兴市第二医院 | A kind of nanometer grain preparation method of the double medicines of the load of Tf modification and its application |
| CN110652518A (en) * | 2019-05-05 | 2020-01-07 | 海南亚洲制药股份有限公司 | Targeting type nano drug-loading system and preparation method thereof |
| CN110314151A (en) * | 2019-08-02 | 2019-10-11 | 深圳国佳产业基金管理有限公司 | Medical Metaporous silicon dioxide material and its application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pan et al. | Mesoporous silica nanoparticles (MSNs)-based organic/inorganic hybrid nanocarriers loading 5-Fluorouracil for the treatment of colon cancer with improved anticancer efficacy | |
| Xie et al. | An implantable and controlled drug-release silk fibroin nanofibrous matrix to advance the treatment of solid tumour cancers | |
| ES2553130T3 (en) | Vascular plunger of sodium alginate-paclitaxel microspheres and their preparation | |
| Wang et al. | Toxicity and therapy of cisplatin-loaded EGF modified mPEG-PLGA-PLL nanoparticles for SKOV3 cancer in mice | |
| Shafiq et al. | Reactive oxygen species-based biomaterials for regenerative medicine and tissue engineering applications | |
| CN108938599A (en) | A kind of double medicament-carried nano carriers of cancer target | |
| He et al. | Localized multidrug co-delivery by injectable self-crosslinking hydrogel for synergistic combinational chemotherapy | |
| WO2019127297A1 (en) | Tetravalent platinum compound-bicyclic double bond amphiphilic polymer prodrug, and nanomicelle, preparation method, and application thereof | |
| Dwivedi et al. | Role of gold nanoparticles as drug delivery vehicles for chondroitin sulfate in the treatment of osteoarthritis | |
| Cheng et al. | The optimized drug delivery systems of treating cancer bone metastatic osteolysis with nanomaterials | |
| do Céu Teixeira et al. | Delivery of antimicrobials by chitosan-composed therapeutic nanostructures | |
| Wang et al. | Polycatechol-derived mesoporous polydopamine nanoparticles for combined ROS scavenging and gene interference therapy in inflammatory bowel disease | |
| CN113663079B (en) | Carrier-free self-assembly nano particle and preparation method and application thereof | |
| Wang et al. | Two novel nanoscale preparations of micelle and thermosensitive hydrogel for docetaxel to treat malignant tumor | |
| Chu et al. | Silica-supported near-infrared carbon dots and bicarbonate nanoplatform for triple synergistic sterilization and wound healing promotion therapy | |
| Li et al. | Tumor microenvironment activated nanoreactors for chemiluminescence imaging-guided simultaneous elimination of breast tumors and tumor-resident intracellular pathogens | |
| Chen et al. | Light-triggered OVA release based on CuS@ poly (lactide-co-glycolide acid) nanoparticles for synergistic photothermal-immunotherapy of tumor | |
| Xu et al. | Mild heat-assisted polydopamine/alginate hydrogel containing low-dose nanoselenium for facilitating infected wound healing | |
| Zang et al. | Polymeric indoximod based prodrug nanoparticles with doxorubicin entrapment for inducing immunogenic cell death and improving the immunotherapy of breast cancer | |
| Oh et al. | Reactive oxygen species scavenging nanofibers with chitosan-stabilized Prussian blue nanoparticles for enhanced wound healing efficacy | |
| Cui et al. | How microalgae is effective in oxygen deficiency aggravated diseases? A comprehensive review of literature | |
| Deng et al. | Multifunctional ZnO@ CuS nanoparticles cluster synergize chemotherapy and photothermal therapy for tumor metastasis | |
| Peng et al. | Thermosensitive injectable hydrogel enhances the antitumor effect of embelin in mouse hepatocellular carcinoma | |
| CN104434792A (en) | Polymer micelle, preparation method thereof, antitumor pharmaceutical composition, preparation and preparation method thereof | |
| Qiao et al. | Ultrasound-activated nanosonosensitizer for oxygen/sulfate dual-radical nanotherapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181207 |